Trends in hepatitis B virus resistance to nucleoside/nucleotide analogues in North China from 2009-2016: A retrospective study.
PMID: 29654894
2018
International journal of antimicrobial agents
Abstract: Despite >50% of M204I/V+-L180M among all HBV resistance cases annually and extensive exposure of patients to lamivudine (LAM), telbivudine (LdT) and adefovir dipivoxil (ADV), ETV resistance also showed a dramatically increased incidence, which rose to 17.1% in 2016.
Abstract: whereas M204I and N236T were more predominant in genotype B than genotype C (40.3% vs.
Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
Abstract: 44.33% (524/1182) rtA181T-positive samples were detected with signature drug-resistant mutations, including 325 with adefovir-resistant mutation rtA181V/N236T, 57 with lamivudine-resistant mutation rtM204V/I, 99 with entecavir-resistant mutation rtM204V/I plus rt184/202/250 substitution(s), and 43 with multidrug-resistant mutation rtA181V/N236T + rtM204V/I +- rt184/202/250 substitution(s).
Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Method: Finally, the mutant variants detected were compared among the study groups with special emphasis on HIV co-infected patients who were described before as having HBV drug resistance gene mutations at their YMDD RT motif due to rtM204V/I in particular and the rest RT motif of the polymerase gene in general.
Method: In particular, the HBV-HIV co-infected group was characterized by the YMDD RT associated 3TC/ETV drug resistance gene mutations (rtM204V/I) which appeared as multiple combinations with other mutant va
Hepatitis B infection among HIV infected individuals in Gabon: Occult hepatitis B enhances HBV DNA prevalence.
Abstract: The percentage of resistance to Lamivudine was high (40%) and varied according to the M204V/I motif.
Introduction: A high
Result: All patients with RAM M204V/I received 3TC-based therapy.
Result: The analysis of HBV strains for the S/Pol gene by the MRT online software showed that of the major RAMs, M204V/I was the most frequent (4/10, 40%), followed by its compensatory RAMs; L180M (3/10, 30%) and V173L (2/10, 20%).
Table: M204I
Discussion: For 3 patients, mutations M204V and M180V were present, for 1 patient only the M204I mutation was detected.
Evolution of drug-resistant mutations in HBV genomes in patients with treatment failure during the past seven years (2010-2016).
Abstract: Among the primary NA-resistant mutations, rtM204I (13.44%, 545/4055) occurred more frequently, followed by rtM204V, rtN236T, rtA181T, and rtA181V.
Abstract: For single-base mutations, rtL180M and rtA181V increased gradually during the past seven years, while rtM204I/V and rtN236T decreased after 2015.
Abstract: Moreover, single-base mu
Impacts of HBV rtH55R polymerase substitution on viral replication and rtM204I/V resistance to nucleoside/nucleotide antiviral drugs.
Abstract: In vitro studies suggest that it might play some replication compensatory role in rtM204I mutants under lamivudine treatment.
Abstract: It is frequently found in combination with rtM204I/V substitution under NUC treatment.
Abstract: RESULTS: Among 261 NUC-treated CHB patients, we found a high detection rate of rtM204I/V substitution (30.7% [80/261]).
Abstract: The replication capacity of the rtM204I clone was found to significantly decrease under lamivudine treatment, but this was not found in the rtH55R+rt PMID: 28749433
2017
Viruses
Introduction: According to several clinical practice guidelines and authoritative reviews, NUCr substitutions can be classified into two categories: primary NUCr substitutions at 8 codons (rtI169T, rtA181T/V, rtT184A/C/F/G/I/L/M/S,
Discussion: This suggests that these atypical substitutions might not play important roles in the emergence of NUCr as compared to rtA181T/V, rtS202C/G/I, rtM204I/V and rtM250I/L/V.
Genotyping of HBV and tracking of resistance mutations in treatment-naive patients with chronic hepatitis B.
Abstract: Six patients (7%) exhibited resistance mutations to LAM, ETV, and TDF: two with patterns L180M + M204V and four with other different patterns: L80I + L180M + M204I; L80V + L180M + M204V; M204I; A194T.
Detection of Hepatitis B Virus M204I Mutation by Quantum Dot-Labeled DNA Probe.
Abstract: In CHB, HBV DNA from the serum samples of patients with poor response or virological breakthrough can be hybridized to probes containing the M204I mutation to visualize fluorescence under fluorescence microscopy, where fluorescence intensity is related to the virus load, in our method.
Abstract: These results show that QDs can be used as fluorescent probes to detect viral HBV DNA polymerase gene variation, and is a simple readout system without complex and expensive instruments, which provides an attractive platform for the detection of HBV M204I mutation.
Method: Primers were designed for the mutant gene of HBV polymerase M204I, which were confirmed by the serum samples containing M204I mutation previously de
HBV mutation literature information.
PMID: 
2018
International journal of antimicrobial agents
Browser Board
Co-occurred Entities
Filtrator
ViMRT